Table 4 Selected ongoing immunotherapy clinical trials assessing extracellular vesicle liquid biopsy-based biomarkers in different cancers
Clinical Trials.Gov Identifier | Cancer type, Origin of exosomes | EV biomarker tested | Description |
|---|---|---|---|
NCT04427475 | NSCLC (Plasma) | PD-L1 miRNAs | Changes of PD-L1 and miRNAs expression on exosomes in plasma of NSCLC patients before and after treatment with immunotherapy |
NCT03927898 | Colon cancer (Blood) | PD-L1 | Changes of PD-L1 expression on exosomes in peripheral blood after treatment with the anti-PD1 toripalimab |
NCT04483219 | Colon cancer (Serum) | Exosomes | Exosomes from serum samples of patients during treatment with tyrosine kinase inhibitor in combination with anti-PD1 among microsatellite stable metastatic colorectal cancer patients |
NCT03985696 | Diffuse large B-cell lymphomas (Plasma) | PD-L1 CD20 | PD-L1 and CD20 on exosomes from plasma of diffuse large B-cell lymphomas patients treated with immunotherapy |
NCT05575622 | Hepatocellular carcinoma (Blood) | PD-L1 LAG-3 | PD-L1 and LAG-3 on exosomes from blood of hepatocellular carcinoma patients treated with immunotherapy |
NCT02977468 | Triple negative breast cancer (Serum) | Exosomes | Serum exosomes in treatment-naive triple negative breast cancer patients receiving pembrolizumab in addition to intraoperative radiation therapy |
NCT05744076 (EXOMEL1) | Melanoma (Plasma) | PD-L1 | PD-L1 on exosomes from plasma of melanoma patients before and after treatment with immunotherapy Comparing PD-L1 labeling in exosomes to PD-L1 labeling in plasma and in tumor tissue |
NCT05705583 | Renal cell carcinoma (Blood and urine) | Exosomes Exosomal RNA | Exosomes concentration and their RNA from blood and urine of renal cell carcinoma patients treated with immunotherapy |